TransThera Sciences (Nanjing)

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, TransThera Sciences (Nanjing) sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 1 currently recruiting 6 completed early-phase tilt upper quartile by trial count

TransThera Sciences (Nanjing): 7 sponsored US clinical trials, 1 recruiting.

TransThera Sciences (Nanjing) sponsors 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 6 completed. 1 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cholangiocarcinoma, with 1 trials.

Upper-quartile sponsor footprint

TransThera Sciences (Nanjing) sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

7 total, page 1 of 1

RECRUITING Phase 3

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

NCT05948475
COMPLETED Phase 2

Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

NCT04919642
COMPLETED Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dose of TT-00920 in Healthy Subjects

NCT05043792
COMPLETED Phase 1

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

NCT04742959
COMPLETED Phase 1

Relative Bioavailability Study and Food Effect Study of TT-00420 (Tinengotinib) Capsule and Tablet Formulations in Healthy Volunteers

NCT04705922
COMPLETED Phase 1

Phase I, First-In-Human Study of TT-00920 in Healthy Subjects

NCT04364789
COMPLETED Phase 1

Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer

NCT03654547

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 1
Phase 3 1

Therapeutic Areas

Cholangiocarcinoma 1
Triple Negative Breast Cancer 1
Advanced Solid Tumors 1
Healthy 1

What is open in the TransThera Sciences (Nanjing) pipeline

1 recruiting of 7 indexed (14% open); 6 completed (86%).

Phase mix: 1 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Cholangiocarcinoma (1 trial), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

TransThera Sciences (Nanjing): open-pipeline peers nationwide

Peers matched on 7 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

TransThera Sciences (Nanjing) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40% Total trials Recruiting share TransThera Sciences (Nanjing)3M4Life Research89bioAbbott Diagnostics DivisionAcademic and Community Cancer Research UnitedAdaptive BiotechnologiesAgelessRxAlaska Blind Child Discovery
TransThera Sciences (Nanjing) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

TransThera Sciences (Nanjing) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this TransThera Sciences (Nanjing) page

7 registered trials is a research-attention snapshot, not an endorsement of TransThera Sciences (Nanjing) or any single study.

  • 1 of TransThera Sciences (Nanjing)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Cholangiocarcinoma is the condition TransThera Sciences (Nanjing) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cholangiocarcinoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. TransThera Sciences (Nanjing) pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.